

**Astec LifeSciences Limited**

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecls.com, Tel no.:022-25195768, Fax no.: 022-22618289, Email id: astecinvestors@godrejastec.com

Statement of Unaudited Standalone Financial Results for the Quarter ended 30th June, 2018



Rs. in Lakh (Except per Equity Share data)

Sr. No	Particulars	STANDALONE			
		3 months ended 30th June, 2018	3 months ended 31st March, 2018	Preceding 3 months ended 30th June, 2017	Year ended 31st March, 2018
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from Operations				
	Sales (Refer note 6)	6,501.65	12,557.40	6,866.95	35,980.28
	Other operating income	45.63	278.69	360.10	1,104.24
	Total Revenue from Operations	6,547.28	12,836.09	7,227.05	37,084.52
II	Other Income	1.80	177.93	295.36	810.62
III	Total Income (I+II)	6,549.08	13,014.02	7,522.41	37,895.14
IV	Expenses				
	Cost of materials consumed	6,521.54	6,803.98	5,274.57	22,421.97
	Purchase of Stock-in-Trade	-	-	-	-
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(2,707.26)	1,365.04	(899.56)	1,082.92
	Excise duty	-	-	326.10	326.10
	Employee benefits expense	620.48	548.19	555.86	2,170.82
	Finance costs	268.43	231.02	298.58	1,065.90
	Depreciation and amortisation expense	404.59	399.70	347.90	1,467.27
	Other expenses	1,198.01	1,005.15	1,022.40	4,207.59
	Total expenses (IV)	6,305.79	10,353.08	6,925.85	32,742.57
V	Profit / (loss) before exceptional items and tax (III - IV)	243.29	2,660.94	596.56	5,152.57
VI	Exceptional Items (Refer note 5)	-	-	-	415.21
VII	Profit / (loss) before tax (V+VI)	243.29	2,660.94	596.56	5,567.78
VIII	Tax Expense:				
	(1) Current tax	69.94	968.57	127.31	1,737.13
	(2) Deferred tax	16.08	(17.42)	70.34	206.99
	(3) Tax for earlier years	9.58	-	-	126.58
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	147.69	1,709.79	398.91	3,497.08
X	Profit / (loss) from discontinued operations	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-
XIII	Profit / (loss) for the period (IX + XII)	147.69	1,709.79	398.91	3,497.08
XIV	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	(3.50)	16.62	(10.21)	(14.00)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1.26	(5.75)	3.53	4.85
	B (i) Items that will be reclassified to profit or loss	8.63	68.92	(138.99)	(29.29)
	(ii) Income tax relating to items that will be reclassified to profit or loss	(3.01)	(23.85)	48.10	10.14
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period)	151.07	1,765.73	301.34	3,468.78
XVI	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,954.52	1,952.77	1,951.65	1,952.77
XVII	Other Equity excluding Revaluation Reserve	-	-	-	15,015.92
XVIII	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinued operations) (non-annualised) :				
	(1) Basic	0.08	8.76	2.04	17.91
	(2) Diluted	0.08	8.74	2.04	17.88

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by Audit Committee and has been approved by the Board of Directors at its Meeting held on Wednesday, 1st August, 2018. These results have been subjected to a limited review by the Statutory Auditors of the Company.
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards (Ind-AS) notified under the Companies (Indian Accounting Standards) Rules, 2015.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- Figures of corresponding previous period have been re-grouped/re-classified wherever necessary, to conform to this period's classification.
- Exceptional Items (as disclosed in the columns "Year ended 31st March, 2018") comprises (a) gain on mutually cancelled agreement for supply of product with one of its multi-national customer aggregating Rs. 1,932.83 Lakh; (b) inventory written off aggregating Rs. 727.83 Lakh; and (c) property, plant & equipment written off aggregating Rs. 789.79 Lakh.
- According to the requirements of Ind-AS and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, revenue for the corresponding previous Quarter ended 30th June, 2017 and for the Financial Year ended 31st March, 2018 were and are reported inclusive of Excise Duty.
The Government of India has implemented Goods and Service Tax ("GST") from 1st July, 2017 replacing Excise duty, Service Tax and various other indirect taxes. As per Ind AS 18, the revenue for the Quarters ended 30th June, 2018 and 31st March, 2018 is reported net of GST. Had the previously reported revenues were shown net of excise duty, comparative revenue of the Company would have been as follows:

(Rs. in Lakh)

Particulars	3 months ended 30th June, 2018	3 months ended 31st March, 2018	Preceding 3 months ended 30th June, 2017	Year ended 31st March, 2018
Sales (Net of Excise Duty)	6,501.65	12,557.40	6,540.85	35,654.18

For Astec LifeSciences Limited

Ashok Hirmath
Managing Director
DIN :- 00349345

Wednesday, 1st August, 2018, Mumbai





Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli(East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.:022-25195768, Fax no.: 022-22618289, Email id: astecinvestors@godrejastec.com

Statement of Unaudited Consolidated Financial Results for the Quarter ended 30th June, 2018



Sr. No	Particulars	Rs. in Lakh (Except per Equity Share data)			
		CONSOLIDATED			
		3 months ended 30th June, 2018	3 months ended 31st March, 2018	Preceding 3 months ended 30th June, 2017	Year ended 31st March, 2018
	(Unaudited)	(Audited)	(Unaudited)	(Audited)	
I	Revenue from Operations				
	Sales (Refer note 6)	6,501.65	12,557.20	6,866.95	35,980.08
	Other operating income	45.63	278.89	360.10	1,104.44
	Total Revenue from Operations	6,547.28	12,836.09	7,227.05	37,084.52
II	Other Income	1.80	177.93	295.36	810.62
III	Total Income (I+II)	6,549.08	13,014.02	7,522.41	37,895.14
IV	Expenses				
	Cost of materials consumed	6,521.54	6,803.98	5,274.57	22,421.97
	Purchase of Stock-in-Trade	-	-	-	-
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(2,707.26)	1,365.04	(899.56)	1,082.92
	Excise duty	-	-	326.10	326.10
	Employee benefits expense	620.48	548.19	555.86	2,170.82
	Finance costs	268.43	231.10	298.58	1,066.03
	Depreciation and amortisation expense	404.81	399.92	348.12	1,468.15
	Other expenses	1,196.29	999.41	1,021.66	4,203.20
	Total expenses (IV)	6,304.29	10,347.64	6,925.33	32,739.19
V	Profit / (loss) before exceptional items and tax (III - IV)	244.79	2,666.38	597.08	5,155.95
VI	Exceptional Items (Refer note 5)	-	-	-	415.21
VII	Profit / (loss) before tax (V+VI)	244.79	2,666.38	597.08	5,571.16
VIII	Tax Expense:				
	(1) Current tax	70.35	969.83	128.05	1,738.51
	(2) Deferred tax	16.31	(16.71)	70.34	207.77
	(3) Tax for previous years	9.58	(5.44)	-	121.14
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	148.55	1,718.70	398.69	3,503.74
X	Profit / (loss) from discontinued operations	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-
XIII	Profit / (loss) for the period (IX + XII)	148.55	1,718.70	398.69	3,503.74
XIV	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	(3.50)	16.62	(10.21)	(14.00)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1.26	(5.75)	3.53	4.85
	B (i) Items that will be reclassified to profit or loss	8.62	68.53	(138.63)	(29.88)
	(ii) Income tax relating to items that will be reclassified to profit or loss	(3.01)	(23.85)	48.10	10.14
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period)	151.92	1,774.25	301.48	3,474.85
XVI	Net Profit/(loss) attributable to:				
	- Owners	148.35	1,715.70	387.56	3,490.40
	- Non controlling interests	0.20	3.00	11.13	13.34
	Total Comprehensive Income attributable to:				
	- Owners	151.72	1,771.25	290.35	3,461.51
	- Non controlling interests	0.20	3.00	11.13	13.34
XVII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,954.52	1,952.77	1,951.65	1,952.77
XVIII	Other Equity excluding Revaluation Reserve	-	-	-	15,012.25
XIX	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinued operations) (non-annualised) :				
	(1) Basic	0.08	8.78	2.04	17.88
	(2) Diluted	0.08	8.77	2.04	17.84

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by Audit Committee and has been approved by the Board of Directors at its Meeting held on Wednesday, 1st August, 2018. These results have been subjected to a limited review by the Statutory Auditors of the Company.
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards (Ind-AS) notified under the Companies (Indian Accounting Standards) Rules, 2015.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- Figures of corresponding previous period have been re-grouped/re-classified wherever necessary, to conform to this period's classification.
- Exceptional Items (as disclosed in the columns "Year ended 31st March, 2018") comprises (a) gain on mutually cancelled agreement for supply of product with one of its multi-national customer aggregating Rs. 1,932.83 Lakh; (b) inventory written off aggregating Rs. 727.83 Lakh; and (c) property, plant & equipment written off aggregating Rs. 789.79 Lakh.
- According to the requirements of Ind-AS and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, revenue for the corresponding previous Quarter ended 30th June, 2017 and for the Financial Year ended 31st March, 2018 were and are reported inclusive of Excise Duty. The Government of India has implemented Goods and Service Tax (GST) from 1st July, 2017 replacing Excise duty, Service Tax and various other indirect taxes. As per Ind AS 18, the revenue for the Quarters ended 30th June, 2018 and 31st March, 2018 is reported net of GST. Had the previously reported revenues were shown net of excise duty, comparative revenue of the Company would have been as follows:

Particulars	(Rs. in Lakh)			
	3 months ended 30th June, 2018	3 months ended 31st March, 2018	Preceding 3 months ended 30th June, 2017	Year ended 31st March, 2018
Sales (Net of Excise Duty)	6,501.65	12,557.20	6,540.85	35,653.98

For Astec LifeSciences Limited

Ashok Hiremath
Managing Director
DIN :- 00349345

Wednesday, 1st August, 2018, Mumbai

